ClinicalTrials.gg
CompletedNCT00367055Updated Jul 27, 2010Results posted

Rosiglitazone-Metformin Combination Versus Metformin-Sulfonylurea Combination On Beta-Cell Function In Type 2 Diabetes

A Phase 4 interventional study of rosiglitazone-metformin and Metformin in Type 2 Diabetes Mellitus, sponsored by GlaxoSmithKline. Completed. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2010-07-27.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
163rd of 287
84 · median 100
Started
2004
with 7 others
Phase 4
98 of 293
6 open now
Registered
35th of 293
by date
Lead sponsor
12 of 293
GlaxoSmithKline

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 163rd largest by enrollment of the 287 interventional ones that give a count, is one of 8 that started in 2004, is one of 98 in phase 4, and was the 35th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

It has been shown in previous study that progressive glycemic deterioration was associated with progressive loss of b-cell function, measured by the decrease in plasma insulin levels, irrespective of the therapy used (diet, sulfonylureas or metformin).There is growing evidence that thiazolidinediones could have a positive action on the b-cell function. But it has not yet been demonstrated that they could protect from a deterioration in insulin secretion in the long term. So, it appears interesting to study the long term evolution of the b-cell function and the possible protection with rosiglitazone in patients with type 2 diabetes showing evidence of loss of b-cell function with metformin alone.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Beta cell function
  • Type 2 diabetes
  • Combination treatment
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females 40 to 75 years of age (inclusive at the time of screening)
  • Type 2 diabetes mellitus as defined by the WHO criteria, diagnosed for at least 1 year
  • Subjects receiving 1.5 to 3g of metformin alone at a constant dose for at least 8 weeks prior to visit 1
  • Patients with 6.5% \< > 8% at visit 1 and visit 2
  • 25 \< \< 35

Exclusion criteria

EXCLUSION CRITERIA:

  • Patient with type 1 diabetes
  • Treatment with other hypoglycaemic agents than metformin in the last 3 months
  • FPG >200 mg/dL at visit 2
  • to the studied treatments (rosiglitazone, metformin chlorhydrate, gliclazide)
  • Congestive heart failure ( class I to IV), unstable or severe angina, recent myocardial infarction
  • Respiratory insufficiency
  • Subjects who have required the use of insulin for glycaemic control in the past 6 months prior to visit 1 (except during pregnancy or acute episodes such as hospitalization, trauma or infection) or subjects with a history of metabolic acidosis including diabetic ketoacidosis
  • Anemia defined by concentration \<11.0 g/dL for males and \<10.0 g/dL for females
  • Renal disease or renal dysfunction, e.g. as suggested by serum creatinine levels ≥135.0 µmol/L in males and ≥110.0 µmol/L in females and/or \<40 mL/min
  • Presence of hepatic disease, with , AST, total , alkaline phosphatase >2.5 times the reference range
  • Subjects with chronic diseases requiring periodic ot intermittent treatment with oral or IV
  • Subjects receiving danazol, miconazole or phenylbutazone
  • Active alcohol, drug or medication abuse within the last 6 months or any condition that would indicate the likelihood of poor subject compliance
  • Women who are lactating, pregnant or planning to become pregnant
  • Any clinically significant abnormality identified at screening which, in the investigator's judgement, makes the subject unsuitable for inclusion in the study
  • Use of any other agent within 30 days or 5 half-lives (whichever is longer) prior to visit 1
  • Subjects who receive or anticipate receiving radiocontrast dye during the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Interventions

  • Drugrosiglitazone-metformin
  • Drugmetformin+ gliclazide

    Drug pages: Metformin · Gliclazide

    Also known as: rosiglitazone-metformin, Metformin

06

What researchers measure

Primary outcomes

  1. Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment

    Change from baseline in the insulin secretory capacity was measured by the assesment of blood insulin concentrations (conc.) using the hyperglycaemic clamp (HC) technique, per intravenous glucose perfusion by a catheter. Change from baseline for insulin conc peaks (highest conc level) was calculated as the Month 36 value minus the baseline value. Insulin secretion was assessed by calculating AUC during the first 10 minutes of HC (incremental and total AUC0-10 min) and the AUC after the first 10 minutes of the HC (10-180min).

    Time frame: Baseline and Month 36

Secondary outcomes

  1. Median Change From Baseline in the Ratio M/I After a 36-month Treatment

    Time frame: Baseline and Month 36

  2. Median Change From Baseline in the Insulin Secretion Capacity After an 18-month Treatment

    Change from baseline was calculated as the Month 18 value minus the baseline value. Insulin secretion capacity is measured in blood (blood level of insulin) and is a response of the pancreatic beta-cells to hyperglycemia induced by a glucose IV bolus, then infusion. Hyperglycemic clamp (HC) is a reference technique to evaluate the initial and the secondary phases of insulin secretion.

    Time frame: Baseline and Month 18

  3. Mean Change From Baseline in HbA1c at Month 36

    Change from baseline was calculated as the Month 36 value minus the baseline value. HbA1c levels were measured by blood draw.

    Time frame: Baseline and Month 36

  4. Mean Change From Baseline in FBG at Month 36

    Change from baseline was calculated as the Month 36 value minus the baseline value. FBG levels were measured by blood draw.

    Time frame: Baseline and Month 36

  5. Median Change From Baseline in Insulin Resistance Index (HOMA-IR) After a 36-month Treatment

    Time frame: Baseline and Month 36

  6. Median Change From Baseline in Beta Cell Function Index (HOMA-beta) After a 36-month Treatment

    Time frame: Baseline and Month 36

  7. Mean Change From Baseline in CPP Total and Incremental AUC T0-T30 After a 36-month Treatment

    Time frame: Baseline and Month 36

  8. Mean Change From Baseline in CPP Concentration Peak and Incremental Concentration Peak T0-T30 After a 36-month Treatment

    Time frame: Baseline and Month 36

  9. Mean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36

    Change from baseline was calculated as the Month 18 and 36 values minus the baseline value. Insulin sensitivity is measured as the quantity of glucose metabolized per unit of plasma insulin concentration.

    Time frame: Baseline and Months 18 and 36

07

Results

Posted Nov 5, 2009

Participant flow

Participant flow — Overall Study
MilestoneRosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/Day
Started4341
Completed3230
Not completed1111
Withdrew: Adverse event63
Withdrew: Patient's willing32
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up11
Withdrew: Protocol violation01
Withdrew: Stopping criterion met01
Withdrew: Participant living too far from hospital01

Outcome measures

PrimaryMedian Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment

Change from baseline in the insulin secretory capacity was measured by the assesment of blood insulin concentrations (conc.) using the hyperglycaemic clamp (HC) technique, per intravenous glucose perfusion by a catheter. Change from baseline for insulin conc peaks (highest conc level) was calculated as the Month 36 value minus the baseline value. Insulin secretion was assessed by calculating AUC during the first 10 minutes of HC (incremental and total AUC0-10 min) and the AUC after the first 10 minutes of the HC (10-180min).

Time frame:
Baseline and Month 36
Reported as:
Median · picomoles/L per minute (pmol/L*min)
Median Change From Baseline in the Insulin Secretory Capacity After a 36-month Treatment
picomoles/L per minute (pmol/L*min)Rosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/Day
Total AUC(0-10 min), n=24, 26-3.9 (-688.3 to 2211.2)-75.3 (-919.9 to 1507.1)
Incremental AUC(0-10 min), n=22, 237.0 (-308.3 to 2781.2)74.6 (-822.2 to 1193.8)
Total concentration peak(0-10 min), n=25, 26-8.6 (-89.6 to 386.5)3.6 (-121.2 to 52.3)
Incremental concentration peak(0-10 min), n=24, 26-1.8 (-60.9 to 443.8)10.8 (-128.3 to 56.6)
Total AUC(10-180 min), n=20, 2440.6 (-411.9 to 500.2)-21.2 (-344.2 to 787.3)
Incremental AUC(10-180 min), n=19, 2467.0 (-304.2 to 518.4)13.6 (-264.9 to 793.4)
Total concentration peak(10-180 min), n=27, 297.9 (-223.0 to 286.1)-9.3 (-120.5 to 229.4)
Incremental concentation peak(10-180 min), n=25,2910.8 (-232.3 to 198.6)11.5 (-116.9 to 231.6)
Statistical analysis
  • Rosiglitazone + Metformin 4 mg/2 g/Day vs Gliclazide + Metformin 80 mg/2 g/Day · Van Elteren · p = 0.376 (p value is for Total AUC(0-10 min))
  • Rosiglitazone + Metformin 4 mg/2 g/Day vs Gliclazide + Metformin 80 mg/2 g/Day · Van Elteren · p = 0.990 (p value is for Incremental AUC(0-10 min))
SecondaryMedian Change From Baseline in the Ratio M/I After a 36-month Treatment
Time frame:
Baseline and Month 36

Results for this outcome have not been posted.

SecondaryMedian Change From Baseline in the Insulin Secretion Capacity After an 18-month Treatment

Change from baseline was calculated as the Month 18 value minus the baseline value. Insulin secretion capacity is measured in blood (blood level of insulin) and is a response of the pancreatic beta-cells to hyperglycemia induced by a glucose IV bolus, then infusion. Hyperglycemic clamp (HC) is a reference technique to evaluate the initial and the secondary phases of insulin secretion.

Time frame:
Baseline and Month 18
Reported as:
Median · pmol/L*min
Median Change From Baseline in the Insulin Secretion Capacity After an 18-month Treatment
pmol/L*minRosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/Day
HC, Total AUC(0-10min), n=30, 3118.3 (-1044.7 to 2211.2)-32.3 (-919.9 to 1612.5)
HC, Incremental AUC(0-10min), n=27, 2622.3 (-308.3 to 2781.2)60.7 (-822.2 to 1193.8)
HC, Total AUC(10-180min), n=26, 3055.9 (-411.9 to 500.2)-7.6 (-344.2 to 787.3)
HC, Incremental AUC(10-180min), n=26, 2972.9 (-304.2 to 518.4)14.6 (-264.9 to 1172.7)
Arginine (Arg) test, Total AUC(0-30min), n=25, 2538.4 (-367.0 to 225.0)10.9 (-163.9 to 93.1)
Arg test, Incremental AUC(0-30min), n=25, 2515.1 (-440.3 to 120.9)-8.0 (-153.3 to 49.3)
Arg test, Incremental Conc. peak(0-30 min),n=26,2923.3 (-2531.7 to 766.5)-111.1 (-1125.0 to 499.7)
SecondaryMean Change From Baseline in HbA1c at Month 36

Change from baseline was calculated as the Month 36 value minus the baseline value. HbA1c levels were measured by blood draw.

Time frame:
Baseline and Month 36
Reported as:
Mean · percent change
Mean Change From Baseline in HbA1c at Month 36
percent changeRosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/Day
Mean Change From Baseline in HbA1c at Month 36-0.22 ± 1.30.3 ± 1.2
SecondaryMean Change From Baseline in FBG at Month 36

Change from baseline was calculated as the Month 36 value minus the baseline value. FBG levels were measured by blood draw.

Time frame:
Baseline and Month 36
Reported as:
Mean · millimoles per Liter (mmol/L)
Mean Change From Baseline in FBG at Month 36
millimoles per Liter (mmol/L)Rosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/Day
Mean Change From Baseline in FBG at Month 36-1.6 ± 1.9-0.2 ± 2.4
SecondaryMedian Change From Baseline in Insulin Resistance Index (HOMA-IR) After a 36-month Treatment
Time frame:
Baseline and Month 36

Results for this outcome have not been posted.

SecondaryMedian Change From Baseline in Beta Cell Function Index (HOMA-beta) After a 36-month Treatment
Time frame:
Baseline and Month 36

Results for this outcome have not been posted.

SecondaryMean Change From Baseline in CPP Total and Incremental AUC T0-T30 After a 36-month Treatment
Time frame:
Baseline and Month 36

Results for this outcome have not been posted.

SecondaryMean Change From Baseline in CPP Concentration Peak and Incremental Concentration Peak T0-T30 After a 36-month Treatment
Time frame:
Baseline and Month 36

Results for this outcome have not been posted.

SecondaryMean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36

Change from baseline was calculated as the Month 18 and 36 values minus the baseline value. Insulin sensitivity is measured as the quantity of glucose metabolized per unit of plasma insulin concentration.

Time frame:
Baseline and Months 18 and 36
Reported as:
Mean · micromoles (umol)/kilogram/min/pmol/L
Mean Change From Baseline in Insulin Sensitivity Index at Months 18 and 36
micromoles (umol)/kilogram/min/pmol/LRosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/Day
Month 18-0.00511 ± 0.03451-0.02045 ± 0.05302
Month 360.00040 ± 0.04722-0.01702 ± 0.05109

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosiglitazone + Metformin 4 mg/2 g/Day—8/43 (18.6%)31/43 (72.1%)
Gliclazide + Metformin 80 mg/2 g/Day—12/41 (29.3%)29/41 (70.7%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventRosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/Day
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/433/41
Peritoneal carcinomatosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/432/41
Oedematous pancreatitisGastrointestinal disorders0/431/41
Partial bowel obstructionGastrointestinal disorders0/431/41
ProctorrhagiaGastrointestinal disorders0/431/41
Umbilical herniaGastrointestinal disorders0/431/41
Spinal column stenosisMusculoskeletal and connective tissue disorders0/431/41
Trigger fingerMusculoskeletal and connective tissue disorders0/431/41
Carpal tunnel syndromeNervous system disorders0/431/41
HemiplegiaNervous system disorders0/431/41
Most frequent other events
Showing 10 of 31
Most frequent other events
EventRosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/Day
NasopharyngitisRespiratory, thoracic and mediastinal disorders9/433/41
HypoglycemiaMetabolism and nutrition disorders1/438/41
BronchitisRespiratory, thoracic and mediastinal disorders8/431/41
TendonitisMusculoskeletal and connective tissue disorders1/434/41
Carpal tunnel syndromeNervous system disorders1/434/41
LumbagoMusculoskeletal and connective tissue disorders4/431/41
Knee painMusculoskeletal and connective tissue disorders2/433/41
DiarrheaGastrointestinal disorders3/433/41
Fungal infectionInfections and infestations0/433/41
RhinitisInfections and infestations0/433/41

Baseline characteristics

Age Continuous
Age Continuous(years)Rosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/DayTotal
Mean58.3 ± 8.458.1 ± 8.058.2 ± 8.2
Sex: Female, Male
Sex: Female, Male(Participants)Rosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/DayTotal
Female111627
Male322557
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per square meter (kg/m2))Rosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/DayTotal
<25303
25-30212041
>30192140
FBG
FBG(Millimoles/Liter (mmol/L))Rosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/DayTotal
Mean9.10 ± 1.728.28 ± 1.118.70 ± 1.50
HbA1c
HbA1c(percentage)Rosiglitazone + Metformin 4 mg/2 g/DayGliclazide + Metformin 80 mg/2 g/DayTotal
Mean7.5 ± 0.557.3 ± 0.557.4 ± 0.57
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2009, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2006
First posted
Aug 22, 2006
Start
Oct 2004
Primary completionActual
Oct 2008
CompletionActual
Oct 2008
Results first posted
Nov 5, 2009
Last update
Jul 27, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00367055
Lead sponsor
GlaxoSmithKline
First posted
Aug 22, 2006
Start date
Oct 2004
Primary completion
Oct 2008
Completion
Oct 2008
Results posted
Nov 5, 2009
Last update
Jul 27, 2010

Study contacts

GSK Clinical Trials, MD
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Gliclazide

Start the discussion